OCUMETICS TECHNOLOGY CORP. — Regulatory Filings 2021

Oct 27, 2021

FORM 51-102F3

MATERIAL CHANGE REPORT

ITEM 1

Name and Address of Company:

OCUMETICS TECHNOLOGY CORP. (formerly Quantum Blockchain Technologies Ltd.) (the “ Corporation ”)

2041 Everett Street Abbotsford, BC V2S 7S1

ITEM 2 Date of Material Change:

October 26, 2021

ITEM 3 News Release:

The news release was distributed on October 26, 2021 and filed on SEDAR on October 26, 2021.

ITEM 4 Summary of Material Change:

The Corporation announced that it had has commenced the first phase of a clinical trial program for its initial product, the Bionic Lens.

ITEM 5 Full Description of Material Change:

The Corporation announced that it had commenced the first phase of a clinical trial program for its initial product, the Bionic Lens.

“We’ve been busy since our successful financing and reverse takeover of a public shell in August,” says Dr. Mark Lee, President and CEO of Ocumetics.

“After 14 years of research and development, our founder, Dr. Garth Webb, recently finalized the design of the two primary components of the Bionic Lens, the lens retainer and the lens itself,” adds Dr. Lee. “We subsequently engaged with a partner to design the tooling to be used to fabricate the Bionic Lens components. With the tooling design completed, our partner has fabricated sufficient prototype retainers to commence our studies.”

‘We are delighted to have now entered the first phase of the clinical trials process for the retainer component of the Bionic Lens,” adds Dr. Lee. “Ocumetics will be providing regular updates, as we complete each successive phase of the clinical trials.”

Dr. Garth Webb, Founder, Chief Scientific Officer and Chairman of the Board of Ocumetics, developed the Bionic Lens to address many of the shortcomings of lens replacement options he observed in his professional practice with patients undergoing cataract and other procedures. While existing lens replacement products have improved over the years, the limitations of current technologies were selfevident to Dr. Webb. The Bionic Lens was designed to eliminate the need for corrective lenses for people of all ages without many of the liabilities associated with other alternatives.

{00628691 v1}E-- 1 -

• 2 -

About Ocumetics

Ocumetics Technology Corp. (TSXV:“OTC”) is a Canadian research and product development company that specializes in adaptive lens designs. Ocumetics is in the clinical trial stage of a game-changing technology for the ophthalmic industry - the Bionic Lens. The Bionic Lens is an expandable intraocular lens that fits within the natural lens compartment of the eye to completely eliminate the need for corrective lenses. It re-establishes the natural kinetics of the eye muscles to facilitate the eye’s ability to shift focus effortlessly from distance to near and very near range.

ITEM 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102:

Not Applicable.

ITEM 7 Omitted Information:

Not Applicable.

ITEM 8 Executive Officer:

Further information relating to this Material Change Report may be obtained from:

Mark Lee, President and Chief Executive Officer Telephone: (604) 832-6052

ITEM 9 Date of Report:

October 27, 2021

The foregoing accurately discloses the material change referred to in this report.

{00628691 v1}